What happened: Shares of First Energy (NYSE:FE) spiked on Monday and were up 15% at 10:45 a.m.
Keep Reading →
January 22 - Market Movers, News
Please follow Point72 Asset Management (if you aren't already doing so) to get real-time email alerts whenever we publish an article about Point72 Asset Management or update its...
Keep Reading →
September 13 - Hedge Funds
"U.S. stocks edged lower on Tuesday as weakness in the energy and financial sectors outweighed gains in technology shares.
Keep Reading →
May 30 - Commodities, Futures/Forex, Gold, Market Movers, News, Tech
"U.S. stocks wavered on Wednesday as investors digested a batch of weak corporate earnings and President Donald Trump's dismissal of his FBI chief. At 1:59 p.m.
Keep Reading →
May 10 - Commodities, Futures/Forex, Gold, Market Movers, News, Tech
It's the beginning of a new week and the three major indexes look once again to open relatively flat. Although the U.K.
Keep Reading →
March 20 - News
Array Biopharma Inc (NASDAQ:ARRY) and its partner Pierre Fabre took the opportunity at the Society for Melanoma Research Annual Congress to share results for its COLUMBUS Phase...
Keep Reading →
November 10 - News, Stock Analysis
Today is likely to be a very interesting day in the market following the Trump win. Nonetheless, Array Biopharma Inc (NASDAQ:ARRY) is skyrocketing, and for good reason.
Keep Reading →
November 10 - News, Stock Analysis
In this article, we'll find out why investors are buzzing about two big Warren Buffett favorites, along with three other companies.
Keep Reading →
September 28 - Market Movers, News
The markets are buoyant today after a report showcased a rise in US Consumer Confidence.
Keep Reading →
September 27 - Market Movers, News
It's a red day on Wall Street, as all three major indexes are lower.
Keep Reading →
September 26 - Market Movers, News
Some stocks are nonetheless gaining ground this morning, including Sarepta Therapeutics Inc (NASDAQ:SRPT), At Home Group Inc.
Keep Reading →
September 14 - Market Movers, News
Array Biopharma Inc (NASDAQ:ARRY) just had its latest NDA accepted by the FDA, and the agency has put forward a PDUFA date for the candidate of June 30, 2017.
Keep Reading →
September 2 - News, Stock Analysis
Investors are keenly watching some stocks today, including Micron Technology, Inc. (NASDAQ:MU), Vale SA (ADR) (NYSE:VALE), Transocean LTD (NYSE:RIG), Himax Technologies, Inc.
Keep Reading →
July 1 - Market Movers, News
Array Biopharma Inc (NASDAQ:ARRY) just reported detailed topline from a recently completed oncology pivotal, and alongside the report, announced it expects to submit a New Drug...
Keep Reading →
June 8 - News, Stock Analysis
Redmile Group is a San Francisco-based, healthcare-focused hedge fund founded and managed by Jeremy Green, an Oxford alum with more than 20 years of experience in wealth management...
Keep Reading →
June 3 - Hedge Fund Analysis, Hedge Funds, News
Most securities that cost less than a dinner at a fast-food restaurant are considered to be too risky, with most intra-day traders or other investors usually avoiding these low...
Keep Reading →
May 31 - Hedge Funds, News
When it comes to the risk-reward ratio, there are very few sectors which can match up to healthcare.
Keep Reading →
March 24 - Hedge Funds, News
Individual investors might find hedge fund investing quite expensive, considering the 2-and-2o fee structure most hedge funds employ.
Keep Reading →
January 26 - Hedge Funds, News
The deadline for the current round of 13F filings, for the quarterly period that ended December 31, is February 15.
Keep Reading →
January 12 - Hedge Funds, News
It's Wednesday and the S&P 500 futures are still firmly in the green in pre-market trading despite the fact that the Federal Reserve is set to raise rates in its FOMC meeting ...
Keep Reading →
December 16 - Market Movers, News
Correction: This article has previously mistakenly stated that the Redmile Group had sold shares of Array Biopharma.
Keep Reading →
September 11 - Hedge Funds, News
Jeremy Green, the manager of Redmile Group, is still bullish on Array Biopharma Inc (NASDAQ:ARRY) having further increased his holding of the stock.
Keep Reading →
August 26 - Hedge Funds, News
Jeremy Green’s Redmile Group has just acquired more shares of Array BioPharma Inc. (NASDAQ:ARRY). In a Form 4 filed with the U.S.
Keep Reading →
August 14 - Hedge Funds, News
Mark Lampert’s Biotechnology Value Fund recently filed its 13F with the U.S. Securities and Exchange Commission for the reporting period of March 31.
Keep Reading →
June 10 - Hedge Fund Analysis, Hedge Funds, News
At the moment, there are plenty of metrics investors can use to track their holdings. Two of the most under-the-radar are hedge fund and insider trading interest.
Keep Reading →
September 17 - News
In the financial world, there are a multitude of gauges shareholders can use to analyze Mr. Market. Two of the most innovative are hedge fund and insider trading interest.
Keep Reading →
September 6 - News
In the eyes of many of your fellow readers, hedge funds are viewed as overrated, outdated financial tools of a forgotten age.
Keep Reading →
September 5 - News
At the moment, there are many methods investors can use to analyze Mr. Market. Some of the most innovative are hedge fund and insider trading sentiment.
Keep Reading →
August 30 - News
Around four in 10 Americans live in places where smog can impact their health.
Keep Reading →
August 5 - News
Array Biopharma Inc (NASDAQ:ARRY), a biotech company primarily focused on discovery of drugs for cancer treatment, is making forays into the asthma market.
Keep Reading →
August 1 - News
With the SPDR S&P Biotech Index up 29% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
July 29 - News
The study included 184 patients with mild-to-moderate persistent allergic asthma.
Keep Reading →
July 29 - News
According to most shareholders, hedge funds are seen as slow, old financial vehicles of the past.
Keep Reading →
June 24 - News
Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) was in 11 hedge funds' portfolio at the end of March. OPTR investors should be aware of a decrease in hedge fund interest lately.
Keep Reading →
June 12 - News
Every week at The Motley Fool we reflect on the top stories in the biotech sector in a wrap-up column.
Keep Reading →
June 10 - News
To most market participants, hedge funds are viewed as underperforming, outdated financial vehicles of the past.
Keep Reading →
June 7 - News
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is on the focused approach trajectory, using its solid foundation in the sciences to fill the holes left open by big pharma. Celldex...
Keep Reading →
May 1 - News
To the average investor, there are a multitude of gauges investors can use to monitor their holdings.
Keep Reading →
April 15 - News
For the last several years, Merck & Co., Inc.
Keep Reading →
March 26 - News
Times are changing in the biotech sector.
Keep Reading →
February 6 - News
Last year we screened US-traded biotech stocks for those trading at the steepest discount to the most pessimistic analyst target prices.
Keep Reading →
November 16 - Stock Analysis